The role of vaccines in the COVID-19 pandemic: what have we learned?
F Krammer - Seminars in Immunopathology, 2024 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged late in 2019 and
caused the coronavirus disease 2019 (COVID-19) pandemic that has so far claimed …
caused the coronavirus disease 2019 (COVID-19) pandemic that has so far claimed …
Evaluation of waning of SARS-CoV-2 vaccine–induced immunity: a systematic review and meta-analysis
Importance Estimates of the rate of waning of vaccine effectiveness (VE) against COVID-19
are key to assess population levels of protection and future needs for booster doses to face …
are key to assess population levels of protection and future needs for booster doses to face …
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis …
Background Synthesising evidence on the long-term vaccine effectiveness of COVID-19
vaccines (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 …
vaccines (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 …
[HTML][HTML] COVID-19 vaccination in Korea
WB Park, YH Hwang, HJ Cheong - Infection & Chemotherapy, 2023 - ncbi.nlm.nih.gov
Since December 2020, various coronavirus disease 2019 (COVID-19) vaccines have been
developed and approved. As of February 2023, mRNA vaccines including bivalent vaccines …
developed and approved. As of February 2023, mRNA vaccines including bivalent vaccines …
High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron
Background The elderly are highly vulnerable to severe COVID-19. Waning immunity and
emergence of Omicron have caused concerns about reduced effectiveness of COVID-19 …
emergence of Omicron have caused concerns about reduced effectiveness of COVID-19 …
[PDF][PDF] Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: interim guidance, first issued 8 January …
World Health Organization - 2021 - apps.who.int
Background This interim guidance has been developed on the basis of the advice issued by
the Strategic Advisory Group of Experts (SAGE) on Immunization at its extraordinary meeting …
the Strategic Advisory Group of Experts (SAGE) on Immunization at its extraordinary meeting …
Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a …
R Sunagar, SD Prasad, R Ella, KM Vadrevu - Frontiers in Immunology, 2022 - frontiersin.org
Most if not all vaccine candidates developed to combat COVID-19 due to SARS-CoV-2
infection are administered parenterally. As SARS-CoV-2 is transmitted through infectious …
infection are administered parenterally. As SARS-CoV-2 is transmitted through infectious …
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens
Background Both infection and vaccination, alone or in combination, generate antibody and
T cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
T cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
[HTML][HTML] Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha-and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS …
AMC Rose, N Nicolay, VS Martín… - …, 2023 - eurosurveillance.org
Introduction Two large multicentre European hospital networks have estimated vaccine
effectiveness (VE) against COVID-19 since 2021. Aim We aimed to measure VE against …
effectiveness (VE) against COVID-19 since 2021. Aim We aimed to measure VE against …
Effectiveness of BNT162b2 BA. 4/5 bivalent mRNA vaccine against symptomatic COVID-19 among immunocompetent individuals testing at a large US retail pharmacy
AE Rudolph, FL Khan, A Shah, TG Singh… - The Journal of …, 2024 - academic.oup.com
Background Data on the effectiveness of BA. 4/5 bivalent vaccine stratified by age and prior
infection are lacking. Methods This test-negative study used data from individuals≥ 5 years …
infection are lacking. Methods This test-negative study used data from individuals≥ 5 years …